Novavax, Inc. (NASDAQ:NVAX) is back in the spotlight as its stock skyrockets following a wave of positive news about its COVID-19 vaccine.
The FDA has notified Novavax that it completed the filing review of the final portion of its Biologics License Application for its COVID-19 vaccine, setting a PDUFA review goal date for April 2025.
This update comes just as an FDA advisory committee voted to recommend updated vaccines for the JN.1-lineage composition. Novavax expects to be ready for delivery by September, pending authorization.
More on the Novavax buzz, here: Novavax Stock Rallies In Pre-Market As Company Plans To Deliver Covid-19 Vaccine By September
Novavax Stock Experiencing High Trading Volume
This news has propelled Novavax shares higher, with the stock trading up …